Geron Corporation

NasdaqGS GERN

Geron Corporation Price to Sales Ratio (P/S) on January 14, 2025: 60.29

Geron Corporation Price to Sales Ratio (P/S) is 60.29 on January 14, 2025, a -98.68% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Geron Corporation 52-week high Price to Sales Ratio (P/S) is 7,996.83 on March 20, 2024, which is 13,164.81% above the current Price to Sales Ratio (P/S).
Geron Corporation 52-week low Price to Sales Ratio (P/S) is 60.29 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Geron Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 2,622.00.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: GERN

Geron Corporation

CEO	Dr. John A. Scarlett M.D.
IPO Date	July 31, 1996
Location	United States
Headquarters	919 East Hillsdale Boulevard
Employees	141
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Key trends

Past 5 years